For patients with established cardiovascular disease and atrial fibrillation, warfarin treatment correlates with a lower risk of a composite of death, myocardial infarction (MI), and ischemic stroke, with no increased risk of bleeding.
In a group of septuagenarian patients with atrial fibrillation, followed for up to six years, warfarin use is associated with a significant reduction in all-cause mortality.
Patients who undergo bioprosthetic aortic valve replacement surgery and discontinue anticoagulant treatment within six months have a greater risk of cardiovascular death.
For warfarin-treated patients, carbamazepine co-treatment is associated with subtherapeutic anticoagulative effect and increased warfarin dose requirements, according to a study published online in the Journal of Thrombosis and Haemostasis.
While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.
Treating acute ischemic stroke patients who are warfarin users with tissue plasminogen activator (tPA) does not increase the risk of intracranial hemorrhage (ICH).
In the 90 days following a gastrointestinal tract bleeding (GIB) event, patients who do not resume warfarin therapy experience an increased rate of thrombosis and death.
Use of warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (AF) is associated with a low risk of stroke or systemic embolism.
For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin vs. dabigatran etexilate (DE), according to a study published in the Journal of the American College of Cardiology.
American College of Cardiology 2011
A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.